Evaluation of nusinersen on impact of caregiver experience and HRQOL in later-onset spinal muscular atrophy (SMA): results from the phase 3 CHERISH trial (1429)
Objective: The objective of this study was to compare health-related quality of life (HRQoL)
from the Phase 3 CHERISH trial among nusinersen vs. sham-controlled patients …
from the Phase 3 CHERISH trial among nusinersen vs. sham-controlled patients …
[PDF][PDF] Drug Registration-a necessary but not sufficient condition for good quality drugs–a preliminary analysis of 12 countries
R Bate, E Putze, S Naoshy, A McPherson… - Africa Fighting Malaria, 2010 - aei.org
Summary As the United States has demonstrated over the past century, drug quality is partly
dictated by the drug regulatory environment. Without at least basic quality control, cheats …
dictated by the drug regulatory environment. Without at least basic quality control, cheats …
Concepts important for multiple sclerosis patient caregivers: Systematic literature review of qualitative studies (P2. 196)
S Naoshy, J Ting, C Watson, D Jurado, C Acquadro… - Neurology, 2016 - AAN Enterprises
Objective: To identify concepts that are important to caregivers of patients with multiple
sclerosis (MS). Background: MS is an unpredictable and heterogeneous disease that …
sclerosis (MS). Background: MS is an unpredictable and heterogeneous disease that …
Measuring upper limb function in multiple sclerosis: Enhancing the ABILHAND's performance
S Cano, S Cleanthous, P Marquis, J Hobart… - Value in …, 2015 - valueinhealthjournal.com
Objectives ASCEND is a phase 3, randomized, double-blind, placebo-controlled trial
assessing whether natalizumab slows disability progression in secondary progressive …
assessing whether natalizumab slows disability progression in secondary progressive …
The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup of patients (pts) in the velour trial stratified by first-line progression≥ 9 …
PM Hoff, G Van Hazel, D Cunningham, D Arnold… - 2014 - ascopubs.org
3639 Background: The addition of B to an oxaliplatin-based regimen in 1st line metastatic
colorectal cancer (mCRC) pts has shown a median progression free survival (PFS) of 9.4 …
colorectal cancer (mCRC) pts has shown a median progression free survival (PFS) of 9.4 …
A hospital budget impact model to compare stem cell mobilisation strategies: impact of primary research and direct stakeholder engagement
IS Jensen, RJ Halbert, G Rossi, S Naoshy… - European Journal of …, 2015 - ejhp.bmj.com
Objectives There is a dearth of published health economic evidence on stem cell
mobilisation (SCM) that can be leveraged effectively for decision making. Our objective was …
mobilisation (SCM) that can be leveraged effectively for decision making. Our objective was …
Drug Registration: A Necessary but Not Sufficient Condition for Good Quality Drugs-A Preliminary Analysis of Twelve Countries
R Bate, L Mooney, E Putze, A McPherson, S Naoshy - 2010 - policycommons.net
There is a tacit assumption amongst healthcare workers that all drugs of the same
therapeutic type, whether innovator brands, generic brands, or a variety of copies of the …
therapeutic type, whether innovator brands, generic brands, or a variety of copies of the …
Survival outcomes in US patients with metastatic colorectal cancer: A retrospective database analysis.
KB Knopf, SU Iqbal, SF Thompson, E Malangone… - 2013 - ascopubs.org
e14576 Background: An increase in survival seen in recent years in patients with metastatic
colorectal cancer (mCRC) has been attributed to improvements in treatments, including …
colorectal cancer (mCRC) has been attributed to improvements in treatments, including …
Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany
C Watson, C Prosser, S Braun… - ClinicoEconomics …, 2017 - Taylor & Francis
Background Multiple sclerosis (MS), a progressive neurodegenerative disease, greatly
impacts the quality of life and economic status of people affected by this disease. In …
impacts the quality of life and economic status of people affected by this disease. In …
Burden of illness in second-line colorectal cancer: A systematic literature review.
E Priedane, Y Xu, D Wilson, JG Jasso Mosqueda… - 2012 - ascopubs.org
e14061 Background: Colorectal cancer (CRC) is the third and second most common cancer
in males and females, respectively, worldwide. Based on cases diagnosed in 2008, the age …
in males and females, respectively, worldwide. Based on cases diagnosed in 2008, the age …